Indianapolis, IN
Ketamine Therapy clinics in Indianapolis
Ketamine therapy in Indianapolis is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to IU Health, Ascension St Vincent, and Community Health Network. Demand reflects a pharma-industry (Lilly) and insurance-driven patient base and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in Indianapolis, Indiana also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Indiana Medical Licensing Board rules on delegation and physician supervision shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in Indianapolis, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
Integrated Health Solutions
- NAD IV Therapy
- Vitamin IV Therapy
- Biofeedback Therapy
- IV Therapy
- IV Hydration
Indy Behavioral Health
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
Regulatory context
A note on Indiana's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 139 / Psilocybin Research (2024)
Authorized clinical research on psilocybin for treatment-resistant mental health conditions at Indiana universities; no therapeutic access framework. -
Indiana Controlled Substances Act
Mirrors federal scheduling.
Indiana enforces federal scheduling. The Indiana Medical Licensing Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Indiana INSPECT PDMP requires controlled substance reporting.